Finch Therapeutics Group (Finch Therapeutics Group) 5-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Finch Therapeutics Group 5-Year Dividend Growth Rate?

Finch Therapeutics Group's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Finch Therapeutics Group's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Finch Therapeutics Group's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Finch Therapeutics Group's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Finch Therapeutics Group's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Finch Therapeutics Group's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Finch Therapeutics Group's 5-Year Dividend Growth Rate falls into.

Finch Therapeutics Group 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Finch Therapeutics Group (OTCPK:FNCH) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Finch Therapeutics Group's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-2.389
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Finch Therapeutics Group (Finch Therapeutics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (OTCPK:FNCH) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143

Website

https://www.finchtherapeutics.com

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

Executives

Jeffery A Smisek	director	1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf	director	400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault	officer: Chief Financial Officer
Matthew P. Blischak	officer: Chief Executive Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein	officer: Chief Operating Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante	director	BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney	director	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft	director	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange	director	28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry	officer: Chief Financial Officer	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam	officer: Chief Medical Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143